CA2039420A1 - Treatment of cataract with 15-keto-prostaglandin compounds - Google Patents

Treatment of cataract with 15-keto-prostaglandin compounds

Info

Publication number
CA2039420A1
CA2039420A1 CA2039420A CA2039420A CA2039420A1 CA 2039420 A1 CA2039420 A1 CA 2039420A1 CA 2039420 A CA2039420 A CA 2039420A CA 2039420 A CA2039420 A CA 2039420A CA 2039420 A1 CA2039420 A1 CA 2039420A1
Authority
CA
Canada
Prior art keywords
alkyl
hydrogen atom
unsubstituted
substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2039420A
Other languages
French (fr)
Other versions
CA2039420C (en
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo KK filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Publication of CA2039420A1 publication Critical patent/CA2039420A1/en
Application granted granted Critical
Publication of CA2039420C publication Critical patent/CA2039420C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Abstract

A pharmaceutical composition for treatment of cataract comprising a 15-ketoprostaglandin compound in association with a pharmaceutically acceptable carrier, diluent or excipient, of the general formula:

(I) wherein L and M are hydrogen atom, hydroxy, lower alkyl, hydroxy(lower)alkyl or oxo, provided that at least one of L
and M is not hydrogen atom and that the five-membered ring may have one or two doubl.e bonds, Q1 and Q2 are hydrogen atom, halogen atom or lower alkyl, D is -CH2-CH2-, -CH=CH-, -CC-or -CO-CH2-, E is -CH2-CH2- or -CH=CH-, W is -CH2-CH2-CH2-, -CH=CH-CH2 or -CH2-CH=CH-, Ra is hydrogen atom, lower alkyl, lower cycloalkyl, monocyclic aryl, monocyclic aryl(lower)alkyl or monocyclic aroyl(lower)alkyl, Rb is single bond or lower alkylene, Rc is lower alkyl which is unsubstituted or substituted with halogen, lower cycloalkyl which is unsubstituted or substituted with lower alkyl, monocyclic aryl which is unsubstituted or substituted with halogen or halo(lower)alkyl, or monocyclic aryloxy which is unsubstituted or substituted with halogen or halo(lower)alkyl, or a pharmaceutically acceptable salt when Ra is hydrogen atom.
CA002039420A 1990-04-04 1991-03-28 Treatment of cataract with 15-keto-prostaglandin compounds Expired - Lifetime CA2039420C (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP9089590 1990-04-04
JP90895/1990 1990-04-04
JP221646/1990 1990-08-22
JP22164690 1990-08-22
JP2931091 1991-01-29
JP29310/1991 1991-01-29

Publications (2)

Publication Number Publication Date
CA2039420A1 true CA2039420A1 (en) 1991-10-05
CA2039420C CA2039420C (en) 1996-12-10

Family

ID=27286510

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002039420A Expired - Lifetime CA2039420C (en) 1990-04-04 1991-03-28 Treatment of cataract with 15-keto-prostaglandin compounds

Country Status (11)

Country Link
US (2) US5212324A (en)
EP (1) EP0453127B1 (en)
KR (1) KR970005172B1 (en)
AT (1) ATE169219T1 (en)
AU (1) AU644148B2 (en)
CA (1) CA2039420C (en)
DE (1) DE69129921T2 (en)
DK (1) DK0453127T3 (en)
ES (1) ES2119762T3 (en)
GR (1) GR3027666T3 (en)
TW (2) TW224942B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205508B (en) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5328933A (en) * 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
SE9303627D0 (en) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for the prevention of cataract
EP0735895B1 (en) * 1993-11-19 2006-01-18 The University Of Sydney A method for preventing or controlling cataract
SE9403160D0 (en) * 1994-09-21 1994-09-21 Pharmacia Ab Method and means for prevention and treatment of secondary cataract
WO1997047595A1 (en) * 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
SK3382000A3 (en) * 1997-09-09 2000-10-09 Procter & Gamble A compound having structure of aromatic substituted prostaglandins and its use for the treatment of bone disorders
ID23971A (en) * 1997-09-09 2000-06-14 Procter & Gamble PROSTAGLANDIN TETRAHIDRO SUBSTITUTEDIC C <16> -C <20> AROMATICS USING AS FP AGONISTS
CN1206997C (en) * 1997-11-28 2005-06-22 株式会社·R-技术上野 Endothelin antagonist
CZ20013174A3 (en) 1999-03-05 2002-02-13 The Procter & Gamble Company C 16 unsaturated FP-selective prostaglandin analogs
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
CA2402597C (en) * 2000-03-16 2011-04-26 Sucampo Ag Composition for use in treatment of ocular hypertension and glaucoma
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
CA2403086C (en) 2000-03-24 2010-08-17 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
AU4472701A (en) * 2000-04-06 2001-10-23 Sucampo Ag Bile secretion promoting composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
MXPA04001604A (en) * 2001-08-23 2004-07-08 Sucampo Ag Method and composition for treatment of ocular hypertension and glaucoma.
CA2458471C (en) 2001-08-31 2012-07-31 Sucampo Ag Prostaglandin analogs as chloride channel opener
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
EP1562604B1 (en) * 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
JP4889219B2 (en) 2002-12-27 2012-03-07 スキャンポ・アーゲー Prostaglandin derivatives for the treatment of abdominal discomfort
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI495471B (en) * 2003-08-12 2015-08-11 R Tech Ueno Ltd Composition and method for promoting hair growth
EP2404606A1 (en) 2003-08-21 2012-01-11 Sucampo AG Ophthalmic compositions comprising a prostaglandin and a viscosity agent
SE0303179D0 (en) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
JP4690814B2 (en) * 2004-08-02 2011-06-01 株式会社アールテック・ウエノ Method for producing prostaglandin derivatives
CN101146541B (en) 2005-01-27 2012-04-11 苏坎波公司 Method and composition for treating central nervous system disorders
EP2329825B1 (en) 2005-03-04 2015-10-07 Sucampo AG Method and composition for treating peripheral vascular diseases
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
BRPI0610557A2 (en) * 2005-04-12 2010-06-29 Sucampo Ag combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders and pharmaceutical composition
MX2008009650A (en) 2006-01-24 2008-11-06 R Tech Ueno Ltd Soft-gelatin capsule formulation.
JP5265369B2 (en) * 2006-01-24 2013-08-14 株式会社アールテック・ウエノ Pharmaceutical composition comprising a bicyclic compound and method for stabilizing the bicyclic compound
CA2645311C (en) 2006-03-13 2014-11-18 R-Tech Ueno, Ltd. Aqueous composition comprising 15-keto-prostaglandin for ophthalmic use
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8609729B2 (en) 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CA2830626A1 (en) 2011-04-07 2012-10-11 Sucampo Ag Method for treating asthenopia
NZ620300A (en) 2011-08-05 2015-09-25 Sucampo Ag Method for treating schizophrenia
AR092821A1 (en) 2012-04-20 2015-05-06 Sucampo Ag CONJUGATE OF GRASO-POLYMER ACID DERIVATIVE
US20150057351A1 (en) 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
WO2016203317A1 (en) 2015-06-19 2016-12-22 Sucampo Ag Pharmaceutical compositions comprising fatty acid derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505386A (en) * 1965-12-29 1970-04-07 Upjohn Co Compounds related to prostaglandins
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (en) * 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo USE OF 15-CETO-PGES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO INCREASE BODY TEMPERATURE.
GB2209939B (en) * 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
ATE78465T1 (en) * 1987-10-02 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk KATHARTICA.
JP2597629B2 (en) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 Stabilization of 13,14-dihydro-15-ketoprostaglandins
JP2597649B2 (en) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 Trachea / bronchodilator
AU619543B2 (en) * 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
ES2055051T3 (en) * 1988-05-23 1994-08-16 Ueno Seiyaku Oyo Kenkyujo Kk A METHOD FOR THE MANUFACTURE OF AN EFFECTIVE MEDICINE TO INCREASE BLOOD PRESSURE.
AU604156B2 (en) * 1988-09-14 1990-12-06 R-Tech Ueno, Ltd. Prostaglandins of the F series
DE68928551T2 (en) * 1988-10-01 1998-04-23 R Tech Ueno Ltd Ocular hypotensive means
TW205508B (en) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo

Also Published As

Publication number Publication date
AU7404791A (en) 1991-10-10
US5686487A (en) 1997-11-11
KR970005172B1 (en) 1997-04-14
DE69129921T2 (en) 1999-01-14
TW249226B (en) 1995-06-11
GR3027666T3 (en) 1998-11-30
EP0453127A3 (en) 1992-12-09
ES2119762T3 (en) 1998-10-16
KR910018027A (en) 1991-11-30
US5212324A (en) 1993-05-18
AU644148B2 (en) 1993-12-02
ATE169219T1 (en) 1998-08-15
EP0453127B1 (en) 1998-08-05
EP0453127A2 (en) 1991-10-23
DE69129921D1 (en) 1998-09-10
DK0453127T3 (en) 1998-10-26
TW224942B (en) 1994-06-11
CA2039420C (en) 1996-12-10

Similar Documents

Publication Publication Date Title
CA2039420A1 (en) Treatment of cataract with 15-keto-prostaglandin compounds
KR910009269A (en) Use of 15-keto-prostaglandin compounds to enhance brain function
ES2005572A6 (en) Pharmaceutically active tetrahydronaphthalene derivatives
LU91293I2 (en) Maropitant or a pharmaceutically acceptable salt of such a compound, including the citrate monohydrate salt. Cerenia
CA2000468A1 (en) Piperidinyl benzimidazoles
CS156792A3 (en) Substituted diaminophthalimides and compounds analogous thereto
USD334662S (en) Treasure chest
CA2530543A1 (en) Illudin analogs as anti-tumor agents
ZA909903B (en) New compounds
EP0381005A3 (en) Ocular lens material
CA2011238A1 (en) Pharmaceutical treatment
CA2037009A1 (en) 15-dehydroxy-16-oxoprostaglandins
CA2049655A1 (en) Pharmaceutical composition for inhibiting platelet aggregation
USD274604S (en) Bottle
EP0625520A3 (en) Thiazolotriazole and thiazolodiazole derivatives with fungicidal activity
USD296845S (en) Garment hanger
CA2045761A1 (en) Ws7622a mono- or di- sulfate, process for preparation thereof and use thereof
EP0373461A3 (en) Benzazoles
USD301993S (en) Safety belt latch assembly
EP0318085A3 (en) Heterazole dialkanoic acids
CA2101575A1 (en) New cycloalkylalkylamines which are sigma-receptor ligands, process for preparing them and their application in therapy
USD274571S (en) Mobile lift
USD319648S (en) Eyeglass retainer with integral floating preserver
FR2656627B1 (en) PAPILLOMAVIRUS PROBE (HVPV63), ESPECIALLY FOR THE IN VITRO DIAGNOSIS OF PAPILLOMAVIRUS INFECTIONS, WHICH MAY BE ACCOMPANIED BY GENITAL NEOPLASIA, AND GENETICALLY AND IMMUNOLOGICALLY LINKED PRODUCTS TO THIS PAPILLOMAVIRUS.
JPS539777A (en) Novel carbostyryl derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry